DAM-57

DAM-57
Clinical data
Other namesDAM-57; N,N-Dimethyllysergamide; DAM; Lysergic acid dimethylamide
Routes of
administration
Oral[1]
Legal status
Legal status
Identifiers
  • (6aR,9R)-N,N-dimethyl-7-methyl-4,6,6a,7,8,9- hexahydroindolo- [4,3-fg] quinoline- 9-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H21N3O
Molar mass295.386 g·mol−1
3D model (JSmol)
  • O=C(N(C)C)[C@@H]3C=C2c4cccc1c4c(c[nH]1)C[C@H]2N(C3)C
  • InChI=1S/C18H21N3O/c1-20(2)18(22)12-7-14-13-5-4-6-15-17(13)11(9-19-15)8-16(14)21(3)10-12/h4-7,9,12,16,19H,8,10H2,1-3H3/t12-,16-/m1/s1 checkY
  • Key:FWHSERNVTGTIJE-MLGOLLRUSA-N checkY
  (verify)

DAM-57, also known as N,N-dimethyllysergamide (DAM) or as lysergic acid dimethylamide, is a derivative of ergine. There has been a single report of observing N,N-dimethyl-D-lysergamide in the illicit drug market.[2] This compound did induce autonomic disturbances at oral levels of some 10 times the dose required for lysergic acid diethylamide (LSD), presumably in the high hundreds of micrograms. There is some disagreement as to whether there were psychic changes observed.[1] It was first described in the scientific literature by Albert Hofmann and colleagues by 1955.[3]

See also

[edit]

References

[edit]
  1. ^ a b Shulgin A, Shulgin A (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. p. 26. ISBN 0-9630096-9-9. OCLC 38503252.; "#26. LSD-25". Erowid.
  2. ^ Clark AB (1973). "Lysergic Acid Diethylamide and Lysergic Acid Dimethylamide". Microgram. 6: 37.
  3. ^ Hofmann A, Stoll A (1955). "Amide der stereoisomeren Lysergsäuren und Dihydro-lysergsäuren. 38. Mitteilung über Mutterkornalkaloide" [Amides of stereoisomeric lysergic and dihydrolysergic acids. 38. Ergot alkaloids]. Helvetica Chimica Acta. 38 (2): 421–433. Bibcode:1955HChAc..38..421S. doi:10.1002/hlca.19550380207. ISSN 0018-019X. Retrieved 5 June 2025.
[edit]